 |
|
JAMA-EXPRESS
Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment
The ISAR-REACT 2 Randomized Trial
Adnan Kastrati, MD;
Julinda Mehilli, MD;
Franz-Josef Neumann, MD;
Franz Dotzer, MD;
Jurriën ten Berg, MD;
Hildegard Bollwein, MD;
Isolde Graf, PharmD;
Maryam Ibrahim, MD;
Jürgen Pache, MD;
Melchior Seyfarth, MD;
Helmut Schühlen, MD;
Josef Dirschinger, MD;
Peter B. Berger, MD;
Albert Schömig, MD; for the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators
JAMA. 2006;295:(doi:10.1001/jama.295.13.joc60034).
ABSTRACT
| |
Context No specifically designed studies have addressed the role of the glycoprotein IIb/IIIa inhibitor abciximab in patients with non–ST-segment elevation acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with 600 mg of clopidogrel.
Objective To assess whether abciximab is associated with clinical benefit in high-risk patients with ACS undergoing PCI after pretreatment with 600 mg of clopidogrel.
Design, Setting, and Patients International, multicenter, randomized, double-blind, placebo-controlled study conducted from March 2003 through December 2005, enrolling 2022 patients (mean age, 66 years) with non–ST-segment elevation ACS undergoing PCI.
Interventions Patients were assigned to receive either abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125-µg/kg per minute [maximum, 10 µg/min] infusion for 12 hours, plus heparin, 70 U/kg of body weight) or placebo (placebo bolus and infusion of 12 hours, plus heparin bolus, 140 U/kg). All patients received clopidogrel, 600 mg, at least 2 hours prior to the procedure, as well as 500 mg of oral or intravenous aspirin.
Main Outcome Measures The primary end point was a composite of death, myocardial infarction, or urgent target vessel revascularization occurring within 30 days after randomization; secondary end points were rates of in-hospital major and minor bleeding.
Results Of 2022 patients enrolled, 1012 were assigned to abciximab and 1010 to placebo. The primary end point was reached in 90 patients (8.9%) assigned to abciximab vs 120 patients (11.9%) assigned to placebo, a 25% reduction in risk with abciximab (relative risk [RR], 0.75; 95% CI, 0.58-0.97; P = .03). Among patients without an elevated troponin level, there was no difference in the incidence of primary end point events between the abciximab group (23/499 patients [4.6%]) and the placebo group (22/474 patients [4.6%]) (RR, 0.99; 95% CI, 0.56-1.76; P = .98), whereas among patients with an elevated troponin level, the incidence of events was significantly lower in the abciximab group (67/513 patients [13.1%]) compared with the placebo group (98/536 patients [18.3%]), which corresponds to an RR of 0.71 (95% CI, 0.54-0.95; P = .02) (P = .07 for interaction). There were no significant differences between the 2 groups regarding the risk of major and minor bleeding as well as need for transfusion.
Conclusions Abciximab reduces the risk of adverse events in patients with non–ST-segment elevation ACS undergoing PCI after pretreatment with 600 mg of clopidogrel. The benefits provided by abciximab appear to be confined to patients presenting with an elevated troponin level.
Trial Registration ClinicalTrials.gov Identifier: NCT00133003
Published online March 13, 2006 (doi:10.1001/jama.295.13.joc60034).
INTRODUCTION
Non–ST-segment elevation acute coronary syndromes (ACS) are associated with an increased risk of death and are a major reason for hospital admissions.1 The sequence of events that typically leads to ACS is characterized by a disrupted atherosclerotic plaque, platelet activation and aggregation, thrombus formation, and microembolizations.2 Aspirin, thienopyridines, and heparins are mainstays of acute medical therapy.3 Because degree of risk at presentation predicts potential benefit from an early invasive strategy,4 current guidelines recommend an early invasive strategy in high-risk patients.1, 5 In addition, deferral of intervention for prolonged antithrombotic pretreatment does not improve the outcome compared with immediate intervention.6
Although percutaneous coronary interventions (PCIs) are an established therapeutic approach in high-risk patients presenting with ACS,7 it is still unclear what the best adjunctive antithrombotic therapies are. There is increasing evidence that treatment with clopidogrel prior to PCI prevents postprocedural ischemic complications8-9 and may attenuate differences observed between 2 antithrombotic regimens given peri-interventionally.10-11 Several studies have shown that a 600-mg loading dose of clopidogrel, compared with the usual 300-mg dose, is as safe and is significantly more rapidly acting and that maximal inhibition of platelet aggregation is achieved within 2 hours after administration.12-14 In the first Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) trial, a 600-mg loading dose of clopidogrel was well tolerated and was associated with such a low frequency of early complications that the use of the glycoprotein (Gp) IIb/IIIa inhibitor abciximab offered no clinically measurable benefit at 30 days in stable patients undergoing elective PCI.15
It is, however, not known whether the antiplatelet effect provided by 600 mg of clopidogrel is so great that it obviates the need for more potent antiplatelet therapies in patients with ACS undergoing PCI. Because there is enhanced platelet activation and aggregation in ACS compared with stable coronary disease,2, 16-17 more potent antiplatelet therapies may be more effective.18 In a meta-analysis of trials involving patients with ACS who were primarily medically managed, Gp IIb/IIIa inhibitors resulted in reduced rates of death and myocardial infarction (MI); this positive effect was largely confined to patients undergoing PCI during index hospitalization.19 However, no specifically designed randomized, placebo-controlled study has addressed the issue of the value of Gp IIb/IIIa inhibitors in high-risk patients with ACS who are undergoing PCI, especially in the era of routine pretreatment with 600 mg of clopidogrel.
Therefore, the objective of the randomized, double-blind, placebo-controlled ISAR-REACT 2 trial was to assess the hypothesis that the Gp IIb/IIIa inhibitor abciximab is a useful therapy in patients with non–ST-segment elevation ACS undergoing PCI, even after pretreatment with a 600-mg loading dose of clopidogrel.
METHODS
Study Population
Patients were enrolled from March 2003 through December 2005. The inclusion criteria were an episode of angina (with an accelerating pattern or prolonged [>20 minutes] or recurrent episodes at rest or with minimal effort) within the preceding 48 hours, accompanied by an elevated troponin T level (>0.03 µg/L) or a new finding of ST-segment depression of at least 0.1 mV or transient (<20 minutes) ST-segment elevation of at least 0.1 mV or new or presumed new bundle-branch block; significant angiographic lesions in a native coronary vessel or venous bypass graft amenable to and requiring a PCI; and written informed consent from the patient.
The exclusion criteria were an ST-segment elevation acute MI (ST-segment  0.1 mV elevation in 2 contiguous electrocardiographic leads persisting for at least 20 minutes); hemodynamic instability; pericarditis; malignancies with life expectancy less than 1 year; increased risk of bleeding (stroke within the previous 3 months, active bleeding or bleeding diathesis, recent trauma or major surgery in the last month, suspected aortic dissection); oral anticoagulation with a coumarin derivative within the previous 7 days; receipt of a Gp IIb/IIIa inhibitor within the previous 14 days; systolic blood pressure of greater than 180 mm Hg unresponsive to therapy; a hemoglobin level less than 100 g/L or hematocrit less than 34%, or platelet count less than 100 x 103 cells/µL or greater than 600 x 103 cells/µL; known allergy to the study medication; and pregnancy (present or suspected).
All patients provided written informed consent prior to catheterization for participation in the study, and the study protocol was approved by the ethics committees of all participating centers in Europe and South America.
Study Protocol
Patients in both study groups received oral clopidogrel, 600 mg, at least 2 hours before PCI. They also received 500 mg of oral or intravenous aspirin. The recommended strategy was an early PCI with stenting within 6 hours from establishment of the diagnosis of ACS. After the decision to perform a PCI but before the guide wire had crossed the lesion, patients were randomly assigned in a double-blind manner using sealed envelopes containing the block randomization sequence for each participating center. Patients in the abciximab group received abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125-µg/kg per minute [maximum, 10 µg/min] infusion for 12 hours), plus heparin, 70 U/kg of body weight. Patients in the placebo group received a placebo bolus and infusion of 12 hours plus heparin bolus, 140 U/kg. Double-blinding was achieved by using vials of similar appearance in the 2 groups.
All patients had troponin levels measured prior to randomization, though not necessarily after PCI. Post-PCI MI criteria were based on creatine kinase CK-MB levels (see below).
Coronary stenting was the preferred PCI according to protocol. Postinterventional therapy included 200 mg of aspirin indefinitely; 75 mg of clopidogrel twice a day until discharge but for no longer than 3 days, followed by daily administration of 75 mg for at least 6 months; as well as other cardiac medications believed to be appropriate by each patient's physician. The protocol provided for the performance of electrocardiograms and collection of blood samples for determination of cardiac enzyme levels, hemoglobin levels, and platelet counts every 8 hours for the first 24 hours after the procedure and daily afterwards, until discharge. Three or more cardiac enzyme measurements were obtained in 87% of the patients; 2 or more measurements were obtained in 98%.
A telephone interview was conducted at 30 days, and patients with cardiac complaints were seen in the outpatient clinic for a complete clinical, electrocardiographic, and laboratory check-up. The local research coordinators collected the data and forwarded them to the data coordinating center. High-quality data were ensured by checking source documentation.
Study End Points and Definitions
The primary end point was the combined cumulative incidence of death from any cause, MI, and urgent target vessel revascularization (coronary artery bypass graft surgery or PCI) due to myocardial ischemia within 30 days after randomization. The diagnosis of MI was made according to the Thrombolysis In Myocardial Infarction (TIMI) criteria20 and based on development of new abnormal Q waves (30 ms in duration and 0.1 mV in depth) in 2 or more contiguous precordial leads or in 2 or more adjacent limb leads, considered to be distinct from the evolution of the index MI; elevation of CK-MB isoenzyme levels (or total CK levels if CK-MB levels were not available) to 3 times the upper limit of normal or greater and, if the pre-PCI CK-MB (or total CK) level was higher than the upper limit of normal, both an increase by at least 50% over the previous value and documentation that the level of CK-MB (or total CK) was decreasing prior to the suspected recurrent MI; recurrent anginal symptoms or new electrocardiographic changes compatible with MI, associated with an elevation of CK-MB level to 50% or more above the peak level prior to randomization for patients in whom there had been no documented decrease of initially elevated CK-MB level prior to randomization; or a CK-MB level more than 10 times the upper limit of normal for patients undergoing coronary artery bypass graft surgery.
The secondary (safety) end points were rates of in-hospital major and minor bleeding. Major and minor bleeding were defined according to the TIMI criteria.20 The criteria for the diagnosis of major bleeding included intracranial or clinically significant overt signs of hemorrhage associated with a greater than 50-g/L decrease in hemoglobin level or an absolute decrease in hematocrit of greater than 15% (when hemoglobin level was not available). The diagnosis of intracranial bleeding required confirmation by computed tomography or magnetic resonance imaging of the head. The criteria for the diagnosis of minor bleeding included observed blood loss and a decrease in hemoglobin level of 30 to 50 g/L (or, when hemoglobin level was not available, a decrease in the hematocrit of 9 to 15 percentage points) or a decrease in hemoglobin level of 40 g/L or greater (or 12% in hematocrit) if no bleeding site was identifiable. We also monitored for the occurrence of profound thrombocytopenia (<20 x 103 platelets/µL) or need for transfusion of blood products.
All events were adjudicated and classified by an event adjudication committee blinded to the assigned treatment.
Statistical Analysis
We assumed a 30-day incidence of the primary end point of 8% in the abciximab group and of 12% in the placebo group, which corresponds to a risk reduction of 33% with abciximab. With 900 patients included in each group, the trial had 80% power to detect this reduction at a 2-sided  error of .05.
All analyses were performed in a blinded manner regarding the randomly assigned treatment. Unblinding of the study groups was performed after completion of the statistical analyses. Data are presented as mean (SD) or as counts or proportions (%). Categorical data were compared with the  2 test or Fisher exact test when expected cell values were less than 5. Continuous data were compared with the t test.
The main analysis used a simple binomial rate ratio to calculate the relative risk (RR) and 95% confidence interval (CI) associated with the use of abciximab compared with placebo regarding the primary end point. The Kaplan-Meier method was used to graphically describe cumulative event incidence with differences checked by means of the log-rank 2 test.
A secondary analysis addressed the comparison of abciximab with placebo in the prespecified subsets defined by the presence of an increased troponin level at baseline (>0.03 µg/L) and of diabetes, as well as by the duration of clopidogrel pretreatment. In a multivariable logistic regression model including the baseline characteristics of the patients, we formerly assessed the interaction of these subset-defining variables (troponin level, diabetes, and duration of clopidogrel pretreatment) with assigned treatment regarding the primary end point. Statistical significance was accepted for a 2-sided P<.05. S-PLUS version 4.5 (Insightful Corp, Seattle, Wash) was used for all statistical analyses.
RESULTS
Figure 1 shows the flow of study participants. Patient characteristics are displayed in Table 1 and are notable for a mean age of 66 years and for high proportions of patients with an elevated troponin level (n = 1049 [52%]), multivessel disease (n = 1503 [74%]), and complex lesions (n = 1632 [81%]). Nearly all patients (1960 [97%]) were treated with coronary stents, which were drug-eluting in approximately half (995 [49%]). There were no differences regarding concomitant drug therapy at discharge between the 2 groups. Thirty-day follow-up was complete in all patients.
|
|
|
|
Figure 1. Flow of Study Participants
ACS indicates acute coronary syndromes; PCI, percutaneous coronary intervention.
|
|
|
|
|
|
|
Table 1. Characteristics of Study Patients
|
|
|
Efficacy Analysis
Figure 2 shows the frequency with which the primary end point was reached in the 30 days after randomization. The primary end point was reached in 90 patients (8.9%) assigned to abciximab vs 120 (11.9%) assigned to placebo. Thus, there was a significant 25% reduction of the risk with abciximab (RR, 0.75; 95% CI, 0.58-0.97; P = .03). Table 2 shows the incidence of ischemic events in the 2 study groups, as well as the RR associated with the use of abciximab. Most of the risk reduction caused by abciximab resulted from a reduction in the occurrence of death and MI.
|
|
|
|
Figure 2. Kaplan-Meier Analysis of Cumulative Incidence of Death, Myocardial Infarction, or Urgent Target Vessel Revascularization for Both Treatment Groups
|
|
|
|
|
|
|
Table 2. Thirty-Day Ischemic Events
|
|
|
Figure 3 shows the frequency with which the primary end point was reached in the subsets of patients defined by the presence or absence of an elevated troponin level. As expected, the incidence of ischemic events was much higher in the subset of patients with elevated troponin levels, irrespective of the study group. There was no difference in the incidence of ischemic events between the abciximab group (23/499 patients [4.6%]) and the placebo group (22/474 patients [4.6%]) among patients without an elevated troponin level (RR, 0.99; 95% CI, 0.56-1.76; P = .98). However, among patients with an elevated troponin level, the incidence of ischemic events was significantly lower in the abciximab group (67/513 patients [13.1%]) compared with the placebo group (98/536 patients [18.3%]) (RR, 0.71; 95% CI, 0.54-0.95; P = .02) (P = .07 for interaction). Figure 4 shows the incidence of the primary end point and the relative risk associated with the use of abciximab in various subgroups. Neither diabetes (P = .37) nor duration of clopidogrel pretreatment (P = .34) showed a significant interaction with assigned treatment regarding the primary end point.
|
|
|
|
Figure 3. Kaplan-Meier Analysis of Cumulative Incidence of Death, Myocardial Infarction, or Urgent Target Vessel Revascularization for Both Treatment Groups in the Subsets With and Without Elevated Troponin Levels (>0.03 µg/L)
|
|
|
|
|
|
|
Figure 4. The 30-Day Incidence and Relative Risk of Death, Myocardial Infarction, or Urgent Target Vessel Revascularization in Various Subgroups
Error bars indicate 95% confidence intervals.
|
|
|
Safety Analysis
Table 3 displays the number of patients who experienced bleeding and those who required blood transfusions or developed profound thrombocytopenia. There were no significant differences between the 2 groups regarding the risk of major and minor bleeding as well as need for transfusion. Profound thrombocytopenia was observed only in the group receiving abciximab (8 patients vs none in the placebo group, P = .008).
|
|
|
|
Table 3. In-Hospital Bleeding Events, Need for Transfusion, and Thrombocytopenia
|
|
|
COMMENT
We assessed the role of the Gp IIb/IIIa inhibitor abciximab in patients with ACS undergoing PCI after pretreatment with a 600-mg loading dose of clopidogrel. Abciximab reduced the risk of adverse ischemic events; the benefit provided by this drug was confined to patients with an elevated troponin level. This benefit was not offset by a significant increase in bleeding.
The patients in the present trial were characterized by a high proportion of elderly patients (mean age, 66 years) with complex lesions (81%) and with elevated troponin levels (52%). An important difference between this and prior trials of Gp IIb/IIIa inhibitors in patients with ACS is that, in the prior trials, randomization was performed before angiography. As a result, in each of those trials some patients without coronary artery disease—and, consequently, with lower risk—were enrolled. In contrast, in the present trial, patients were randomly assigned after the diagnosis of obstructive epicardial coronary artery disease was established angiographically. These characteristics and the trial design increased the risk profile of the patients in this trial and should be taken into account when making comparisons between this and other trials in patients with ACS.7, 22-23
Special consideration should be given to the C7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) trial, which enrolled 1265 patients within 24 hours of diagnostic angiography.24 Among patients with an elevated troponin level in the CAPTURE trial, the combined 30-day incidence of death and MI was 19.6% in the placebo group and decreased to 5.8% in the abciximab group.25 However, patients with refractory angina after diagnostic angiography were excluded from the CAPTURE trial,24 and those included were younger by 5 years and less likely to have diabetes compared with patients enrolled in the ISAR-REACT 2 trial.
We found a 25% reduction of the risk of recurrent ischemic events among patients assigned to abciximab. Notably, the gradient in favor of abciximab was seen for all components of the primary end point—death, MI, and urgent target vessel revascularization—although none reached statistical significance when considered individually. The adverse event rate observed in patients without an elevated troponin level was similar to that seen previously in the first ISAR-REACT trial, an earlier trial of abciximab in stable patients undergoing elective PCI.15 In that subset of patients without elevated troponin levels, as in prior studies,15 abciximab did not provide added clinical benefit to patients pretreated with 600 mg of clopidogrel. In contrast, among patients with an elevated troponin level, the risk of recurrent ischemic events was considerably higher than that in those without elevated troponin levels and was reduced by 29% by abciximab. This is in line with previous studies that have shown that patients with ACS and elevated troponin levels derive the greatest benefit from therapy with Gp IIb/IIIa inhibitors.18
Pretreatment with a loading dose of clopidogrel has become standard therapy in patients undergoing PCI. Recent studies have shown that not only faster but greater platelet inhibition can be achieved by use of a loading dose of 600 mg of clopidogrel as compared with 300 mg.12, 26-27 This has also been associated with better protection from myocardial injury during PCI.28 In stable patients undergoing elective PCI, pretreatment with 600 mg of clopidogrel provides platelet inhibition sufficient to enable a safe procedure without the need of Gp IIb/IIIa inhibitors.15, 29-31 In patients with ACS, however, platelet activation and aggregability are substantially increased, and the concentration of inflammatory mediators is increased as well; both platelet activation and hyperaggregability and an increase in inflammatory mediators correlate with the degree of myocardial damage as assessed by biochemical markers.16, 32-33 Glycoprotein IIb/IIIa inhibitors achieve additional suppression of platelet aggregation26 and the inflammatory response34 from both ACS and PCI beyond that provided by clopidogrel. This may be particularly important in patients with ACS who have elevated troponin levels, offering a possible explanation of the favorable effect achieved by abciximab in such patients in the present study.
Several issues could not be addressed in the present study. Although an increasing number of centers have adopted the strategy of pretreatment with 600 mg of clopidogrel, many centers are still giving a lower dose or no clopidogrel to patients with ACS prior to PCI. Whether the clinical benefit of abciximab might be greater in patients who do not receive pretreatment with 600 mg of clopidogrel is unknown. We also cannot exclude the possibility that a greater benefit from abciximab might have been present had this therapy been initiated earlier, prior to the catheterization laboratory.35 The results of the present study should be considered in the context of the settings in which the study was carried out. All patients were pretreated with 600 mg of clopidogrel and received unfractionated heparin during the procedure. We used a larger heparin bolus than is traditionally used in the United States,36 but, at the same time, there was no activated clotting time guidance and no additional heparin doses were administered during the procedure. Alternative strategies based on the direct thrombin inhibitor bivalirudin administered with or without Gp IIb/IIIa antagonists are currently being evaluated in patients with ACS who are not routinely pretreated with 600 mg of clopidogrel.37 In addition, novel, rapidly acting P2Y12 antagonists such as prasugrel,38 cangrelor,39-40 and AZD614041 are being assessed as alternatives to clopidogrel loading and may modify the benefit profile of abciximab in patients with ACS treated invasively.
CONCLUSION
Abciximab reduces the risk of adverse events in patients with non–ST-segment elevation ACS who are undergoing PCI after pretreatment with 600 mg of clopidogrel. The benefits of abciximab appear to be confined to patients with an elevated troponin level.
AUTHOR INFORMATION
Corresponding Author: Adnan Kastrati, MD, Deutsches Herzzentrum, Lazarettstrasse 36, 80636 Munich, Germany (kastrati{at}dhm.mhn.de).
Published Online: March 13, 2006 (doi:10.1001/jama.295.13.joc60034).
Author Contributions: Drs Kastrati and Schömig had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Kastrati, Berger, Schömig.
Acquisition of data: Mehilli, Neumann, Dotzer, ten Berg, Bollwein, Graf, Ibrahim, Pache, Seyfarth, Schühlen, Dirschinger.
Analysis and interpretation of data: Kastrati, Mehilli, Berger, Schömig.
Drafting of the manuscript: Kastrati, Schömig.
Critical revision of the manuscript for important intellectual content: Mehilli, Neumann, Dotzer, ten Berg, Bollwein, Graf, Ibrahim, Pache, Seyfarth, Schühlen, Dirschinger, Berger.
Statistical analysis: Kastrati.
Obtained funding: Kastrati, Mehilli, Schömig.
Administrative, technical, or material support: Bollwein, Graf, Ibrahim, Seyfarth, Schühlen.
Study supervision: Mehilli, Neumann, Dotzer, ten Berg, Bollwein, Pache, Dirschinger, Schömig.
Financial Disclosures: Dr Kastrati has received lecture fees from Bristol-Myers Squibb, Lilly, and Sanofi-Aventis; Dr Schühlen has received lecture fees from Lilly; Dr Berger has received unrestricted educational grants from Sanofi-Aventis, Lilly, and Sankyo for the Duke Cardiovascular Cath Lab Conference, which he directs, and has also received research support from Guilford and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, and Schering Plough. The other authors reported no financial disclosures.
Funding/Support: This trial was supported in part by the grant KKF 04-03 from Deutsches Herzzentrum, Munich, Germany.
Role of the Sponsor: The Deutsches Herzzentrum had no role in the study design; the collection, analysis, or interpretation of the data; the decision to publish the findings; or the writing of the manuscript.
ISAR-REACT 2 Investigators and Centers: Study Organization: Steering committee: A. Schömig (chair), A. Kastrati (principal investigator), P. Berger; Data and Safety Monitoring Board: J. Mann (chair), F. Hoffmann, M. Schwaiger, K. Ulm (biostatistician); Data Coordinating Center: J. Mehilli, H. Bollwein, C. Vollmer, H. Holle, S. Glaser, K. Hösl, F. Rodrigues, C. Peterle, S. Sunder; Angiographic Core Laboratory: A. Dibra, S. Piniek, S. Mayer, O. Bruskina; ECG Core Laboratory: M. Ibrahim, C. Markwardt, V. Bassignana; Participating Centers and Investigators: Deutsches Herzzentrum, Munich, Germany: J. Pache (principal investigator), C. Schmitt, H. Schühlen, R. Wessely, I. Ott, M. Lampen; Klinikum rechts der Isar, Munich: J. Dirschinger (principal investigator), M. Seyfarth, N. von Beckerath, M. Karch, K. L. Laugwitz; Herz-Zentrum, Bad Krozingen, Germany: F.-J. Neumann (principal investigator), H. J. Büttner, H.-P. Bestehorn, V. Bassignana, K. Peitz, M. Ference, M. Gick, K. Werner, T. Comberg; Klinikum Garmisch-Partenkirchen, Germany: F. Dotzer (principal investigator), C. Glatthor, M. Fleckenstein; St Antonius Ziekenhuis, Nieuwegein, the Netherlands: J. M. ten Berg (principal investigator), E. T. Bal, E. G. Mast, M. J. Suttorp, B. J. W. M. Rensing, F. D. Eefting; Herzzentrum der Segeberger Kliniken, Bad Segeberg, Germany: G. Richardt (principal investigator), P. Meyborg, A. Khattab, R. Toelg; Istituto Dante Pazzanese de Cardiologia, Sao Paolo, Brazil: L. A. Mattos (principal investigators), A. J. Chavez, J. E. Souza, A. Abizaid, A. G. M. R. Sousa.
Author Affiliations: Deutsches Herzzentrum (Drs Kastrati, Mehilli, Graf, Ibrahim, Pache, Schühlen, and Schömig) and First Medizinische Klinik rechts der Isar (Drs Bollwein, Seyfarth, Dirschinger, and Schömig), Technische Universität, Munich, Germany; Herz-Zentrum, Bad Krozingen, Germany (Dr Neumann); Klinikum Garmisch-Partenkirchen, Germany (Dr Dotzer); St Antonius Ziekenhuis, Nieuwegein, the Netherlands (Dr ten Berg); and Duke Clinical Research Institute, Durham, NC (Dr Berger).
REFERENCES
| |
1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-1374.
FREE FULL TEXT
2. Schulman SP. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. JAMA. 2004;292:1875-1882.
FREE FULL TEXT
3. Gluckman TJ, Sachdev M, Schulman SP, Blumenthal RS. A simplified approach to the management of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;293:349-357. [published correction appears in JAMA. 2005;293:1728].
FREE FULL TEXT
4. Morrow DA, Cannon CP, Rifai N, et al, TACTICS-TIMI 18 Investigators. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286:2405-2412.
FREE FULL TEXT
5. Silber S, Albertsson P, Aviles FF, et al, Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J. 2005;26:804-847.
FREE FULL TEXT
6. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. 2003;290:1593-1599.
FREE FULL TEXT
7. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005;293:2908-2917.
FREE FULL TEXT
8. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
PUBMED
9. Steinhubl SR, Berger PB, Mann JT III, et al, CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420. [published correction appears in JAMA. 2003;289:987].
FREE FULL TEXT
10. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
FREE FULL TEXT
11. Lincoff AM, Bittl JA, Harrington RA, et al, REPLACE Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863. [published correction appears in JAMA. 2003;289:1638].
FREE FULL TEXT
12. Müller I, Seyfarth M, Rüdiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001;85:92-93.
FREE FULL TEXT
13. Kandzari DE, Berger PB, Kastrati A, et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol. 2004;44:2133-2136.
FREE FULL TEXT
14. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-2564.
FREE FULL TEXT
15. Kastrati A, Mehilli J, Schühlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004;350:232-238.
FREE FULL TEXT
16. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. J Am Coll Cardiol. 1999;33:634-639.
FREE FULL TEXT
17. Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther. 2004;2:535-545.
PUBMED
18. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. 2000;284:1549-1558.
FREE FULL TEXT
19. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes: gradient of benefit related to the revascularization strategy. Eur Heart J. 2002;23:1441-1448.
FREE FULL TEXT
20. TIMI Study Group. Definitions used in TIMI trials. Available at: http://www.timi.org. Accessed February 1, 2006.21. Ellis SG, Vandormael MG, Cowley MJ, et al, Multivessel Angioplasty Prognosis Study Group. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for participant selection. Circulation. 1990;82:1193-1202.
FREE FULL TEXT
22. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-198.
PUBMED
23. Ferguson JJ, Califf RM, Antman EM, et al, SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45-54.
FREE FULL TEXT
24. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997;349:1429-1435. [published correction appears in Lancet. 1997;350:744].
PUBMED
25. Hamm CW, Heeschen C, Goldmann B, et al, c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med. 1999;340:1623-1629.
FREE FULL TEXT
26. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005;111:1153-1159.
FREE FULL TEXT
27. von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation. 2005;112:2946-2950.
FREE FULL TEXT
28. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005;111:2099-2106.
FREE FULL TEXT
29. Hausleiter J, Kastrati A, Mehilli J, et al. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. J Intern Med. 2004;256:388-397.
PUBMED
30. Mehilli J, Kastrati A, Schühlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004;110:3627-3635.
FREE FULL TEXT
31. Schömig A, Schmitt C, Dibra A, et al. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J. 2005;26:1379-1384.
FREE FULL TEXT
32. Mazzone A, De Servi S, Mazzucchelli I, et al. Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T. Heart. 2001;85:571-575.
FREE FULL TEXT
33. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110:1392-1397.
FREE FULL TEXT
34. Furman MI, Krueger LA, Linden MD, et al. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost. 2005;3:312-320.
PUBMED
35. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004;292:362-366.
FREE FULL TEXT
36. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
PUBMED
37. Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J. 2004;148:764-775.
PUBMED
38. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111:3366-3373.
FREE FULL TEXT
39. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001;85:401-407.
PUBMED
40. Judge HM, Buckland RJ, Holgate CE, Storey RF. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. Platelets. 2005;16:398-407.
PUBMED
41. Cannon CP, Husted S, Storey RF, et al. Safety, tolerability and preliminary efficacy of AZD6140, the first oral reversible ADP receptor antagonist compared with clopidogrel in patients with non-ST segment elevation acute coronary syndrome (the DISPERSE2 study). Presented at: American Heart Association Scientific Sessions 2005; November 15, 2005; Dallas, Tex.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Clopidogrel Treatment Prior to Percutaneous Coronary Intervention: When Enough Isn't Enough
Steven R. Steinhubl and Richard Charnigo
JAMA. 2006;295(13):1581-1582.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Acute Coronary Syndromes: Diagnosis and Management, Part I
Kumar and Cannon
Mayo Clin Proc. 2009;84:917-938.
ABSTRACT
| FULL TEXT
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials
Valgimigli et al.
Eur Heart J 2009;0:ehp376v1-ehp376.
ABSTRACT
| FULL TEXT
Antithrombotics in acute coronary syndromes.
Bonaca et al.
J Am Coll Cardiol 2009;54:969-984.
ABSTRACT
| FULL TEXT
Immediate vs Delayed Intervention for Acute Coronary Syndromes: A Randomized Clinical Trial
Montalescot et al.
JAMA 2009;302:947-954.
ABSTRACT
| FULL TEXT
Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assays
Reichlin et al.
NEJM 2009;361:858-867.
ABSTRACT
| FULL TEXT
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Analysis.
O'Donoghue et al.
J Am Coll Cardiol 2009;54:678-685.
ABSTRACT
| FULL TEXT
New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?
Van de Werf
Eur Heart J 2009;30:1695-1702.
ABSTRACT
| FULL TEXT
Antiplatelet Polypharmacy in Primary Percutaneous Coronary Intervention: Trying to Understand When More Is Better
Abdel-Latif and Moliterno
Circulation 2009;119:3168-3170.
FULL TEXT
Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes
Giugliano et al.
NEJM 2009;360:2176-2190.
ABSTRACT
| FULL TEXT
Use of Guidelines-Recommended Management and Outcomes Among Women and Men With Low-Level Troponin Elevation: Insights From CRUSADE
Halim et al.
Circ Cardiovasc Qual Outcomes 2009;2:199-206.
ABSTRACT
| FULL TEXT
Abciximab in Patients With Acute ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial
Mehilli et al.
Circulation 2009;119:1933-1940.
ABSTRACT
| FULL TEXT
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Sibbing et al.
Eur Heart J 2009;30:916-922.
ABSTRACT
| FULL TEXT
Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions
Angiolillo
Diabetes Care 2009;32:531-540.
FULL TEXT
Avoiding and Managing Bleeding Complications in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
Potsis et al.
ANGIOLOGY 2009;60:148-158.
ABSTRACT
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
Fung et al.
J Am Coll Cardiol 2009;53:837-845.
ABSTRACT
| FULL TEXT
Optimal antiplatelet therapy during percutaneous coronary interventions includes glycoprotein IIb/IIIa inhibitors just eliminate the infusion.
Mahmud and Prasad
J Am Coll Cardiol 2009;53:846-848.
FULL TEXT
Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade: Findings of the ESPRIT Trial
Tcheng et al.
Circ Cardiovasc Interv 2009;2:43-51.
ABSTRACT
| FULL TEXT
Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials
Iijima et al.
Heart 2009;95:107-112.
ABSTRACT
| FULL TEXT
Antiplatelet Agents in the Perioperative Period
O'Riordan et al.
Arch Surg 2009;144:69-76.
ABSTRACT
| FULL TEXT
Bleeding during percutaneous intervention: tailoring the approach to minimise risk
Kinnaird et al.
Heart 2009;95:15-19.
ABSTRACT
| FULL TEXT
The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel: The PRINC (Plavix Response in Coronary Intervention) Trial
Gladding et al.
J Am Coll Cardiol Intv 2008;1:612-619.
ABSTRACT
| FULL TEXT
Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
Lincoff et al.
J Am Coll Cardiol Intv 2008;1:639-648.
ABSTRACT
| FULL TEXT
Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders: A Prospective, Randomized Study
Cuisset et al.
J Am Coll Cardiol Intv 2008;1:649-653.
ABSTRACT
| FULL TEXT
The balance between bleeding and ischaemic complications in percutnaeous coronary intervention practice
Antoniucci
Eur Heart J Suppl 2008;10:J21-J25.
FULL TEXT
Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients With In-Hospital Bleeding
Wang et al.
Circulation 2008;118:2139-2145.
ABSTRACT
| FULL TEXT
Long-term treatment strategies for atherothrombotic disease: do platelets define the course?
Zimarino and De Caterina
Eur Heart J Suppl 2008;10:I8-I13.
ABSTRACT
| FULL TEXT
Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study
Patti et al.
J Am Coll Cardiol 2008;52:1128-1133.
ABSTRACT
| FULL TEXT
What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax?
Williams and Abbott
Circulation 2008;118:1219-1222.
FULL TEXT
Survival Benefit With Concomitant Oral Platelet Therapy After Coronary Angiography and Before Ad Hoc Percutaneous Coronary Intervention
Patel and White
Mayo Clin Proc. 2008;83:978-979.
FULL TEXT
Defining a Role for Novel Biomarkers in Acute Coronary Syndromes
Bonaca and Morrow
Clin. Chem. 2008;54:1424-1431.
ABSTRACT
| FULL TEXT
Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention
Kastrati et al.
NEJM 2008;359:688-696.
ABSTRACT
| FULL TEXT
Prevalence and Prognostic Significance of Preprocedural Cardiac Troponin Elevation Among Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results From the Evaluation of Drug Eluting Stents and Ischemic Events Registry
Jeremias et al.
Circulation 2008;118:632-638.
ABSTRACT
| FULL TEXT
Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome
Dobesh et al.
Am J Health Syst Pharm 2008;65:S22-S28.
ABSTRACT
| FULL TEXT
2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies
Coons and Battistone
The Annals of Pharmacotherapy 2008;42:989-1001.
ABSTRACT
| FULL TEXT
Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8
Widimsky et al.
Eur Heart J 2008;29:1495-1503.
ABSTRACT
| FULL TEXT
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease
Geisler et al.
Heart 2008;94:743-747.
ABSTRACT
| FULL TEXT
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Patrono et al.
Chest 2008;133:199S-233S.
ABSTRACT
| FULL TEXT
Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Harrington et al.
Chest 2008;133:670S-707S.
ABSTRACT
| FULL TEXT
Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) Analysis
Antman et al.
J Am Coll Cardiol 2008;51:2028-2033.
ABSTRACT
| FULL TEXT
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
Kereiakes and Gurbel
J Am Coll Cardiol Intv 2008;1:111-121.
ABSTRACT
| FULL TEXT
N-Terminal B-Type Natriuretic Peptide Assessment Provides Incremental Prognostic Information in Patients With Acute Coronary Syndromes and Normal Troponin T Values Upon Admission
Weber et al.
J Am Coll Cardiol 2008;51:1188-1195.
ABSTRACT
| FULL TEXT
Antiplatelet Therapy for Vascular Interventions
Comerota and Thakur
PERSPECT VASC SURG ENDOVASC THER 2008;20:28-35.
ABSTRACT
Platelets: Inflammatory Firebugs of Vascular Walls
May et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:s5-s10.
ABSTRACT
| FULL TEXT
Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions Appropriateness of Including Bleeding as a Component of a Quadruple End Point.
Ndrepepa et al.
J Am Coll Cardiol 2008;51:690-697.
ABSTRACT
| FULL TEXT
Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era?
Roffi and Mukherjee
Eur Heart J 2008;29:429-431.
FULL TEXT
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial
Ndrepepa et al.
Eur Heart J 2008;29:455-461.
ABSTRACT
| FULL TEXT
Ensuring appropriate use of antiplatelet agents in the treatment of acute coronary syndromes have cardiovascular physicians been given enough grace in getting it right?
Gershlick
Heart 2008;94:135-137.
FULL TEXT
Antiplatelet therapy in acute coronary syndromes
Gitt and Betriu
Eur Heart J Suppl 2008;10:A4-A12.
ABSTRACT
| FULL TEXT
Antiplatelet therapy in percutaneous coronary intervention
Bode and Huber
Eur Heart J Suppl 2008;10:A13-A20.
ABSTRACT
| FULL TEXT
Variability of response to antiplatelet therapy
Storey
Eur Heart J Suppl 2008;10:A21-A27.
ABSTRACT
| FULL TEXT
Platelet Activation in Coronary Artery Disease: Intracardiac vs Peripheral Venous Levels and the Effects of Angioplasty
Jaumdally et al.
Chest 2007;132:1532-1539.
ABSTRACT
| FULL TEXT
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:652-726.
FULL TEXT
A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days
von Beckerath et al.
Eur Heart J 2007;28:1814-1819.
ABSTRACT
| FULL TEXT
Dual antiplatelet therapy in high-risk patients
Van de Werf
Eur Heart J Suppl 2007;9:D3-D9.
ABSTRACT
| FULL TEXT
The Year in Interventional Cardiology
Dixon et al.
J Am Coll Cardiol 2007;50:270-285.
FULL TEXT
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;28:1598-1660.
FULL TEXT
Acute coronary syndromes without ST segment elevation
Peters et al.
BMJ 2007;334:1265-1269.
FULL TEXT
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin
Birnbaum et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;292:H2891-H2897.
ABSTRACT
| FULL TEXT
Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease
Eshaghian et al.
ANN INTERN MED 2007;146:434-441.
ABSTRACT
| FULL TEXT
Acute coronary syndromes, response to clopidogrel, and worsened cardiovascular outcomes: the hen and the egg dilemma
Serebruany
Eur Heart J 2007;28:640-641.
FULL TEXT
Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial
Stone et al.
JAMA 2007;297:591-602.
ABSTRACT
| FULL TEXT
Variability in response to clopidogrel: where is the threshold for 'low response'?: reply
Geisler and Gawaz
Eur Heart J 2007;0:ehl500v1-1.
FULL TEXT
Antiplatelet treatment for coronary heart disease
Clappers et al.
Heart 2007;93:258-265.
FULL TEXT
New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective
Neumann et al.
Eur Heart J Suppl 2007;9:A4-A10.
ABSTRACT
| FULL TEXT
Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight)
Dudek et al.
Eur Heart J Suppl 2007;9:A25-A31.
ABSTRACT
| FULL TEXT
Differences among GP IIb/IIIa inhibitors: different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients
Antoniucci
Eur Heart J Suppl 2007;9:A32-A36.
ABSTRACT
| FULL TEXT
Drive-Through Angioplasty: Is It Safe or Necessary?
Mixon and Dehmer
Circulation 2006;114:2578-2580.
FULL TEXT
A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation
Bertrand et al.
Circulation 2006;114:2636-2643.
ABSTRACT
| FULL TEXT
Bivalirudin for Patients with Acute Coronary Syndromes.
Stone et al.
NEJM 2006;355:2203-2216.
ABSTRACT
| FULL TEXT
Accounting for ACUITY.
Bittl
NEJM 2006;355:2249-2250.
FULL TEXT
Platelet Function Assessment to Predict Outcomes After Coronary Interventions: Hype or Hope?
Alfonso and Angiolillo
J Am Coll Cardiol 2006;48:1751-1754.
FULL TEXT
Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement
Hochholzer et al.
J Am Coll Cardiol 2006;48:1742-1750.
ABSTRACT
| FULL TEXT
Glycoprotein IIb/IIIa Inhibitors in the Elderly: Fear of Age or Age of Fear?
Montalescot
Circulation 2006;114:2004-2006.
FULL TEXT
Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions
Ndrepepa et al.
Circulation 2006;114:2040-2046.
ABSTRACT
| FULL TEXT
Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting
Cuisset et al.
J Am Coll Cardiol 2006;48:1339-1345.
ABSTRACT
| FULL TEXT
Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention
Hamdalla and Steinhubl
Eur Heart J Suppl 2006;8:G20-G24.
ABSTRACT
| FULL TEXT
Triple antiplatelet treatment in patients presenting with non-ST-segment elevation acute coronary syndromes
Bertrand and Van Belle
Eur Heart J Suppl 2006;8:G59-G63.
ABSTRACT
| FULL TEXT
Clinical Guidelines and Practice: In Search of the Truth
Kereiakes and Antman
J Am Coll Cardiol 2006;48:1129-1135.
ABSTRACT
| FULL TEXT
Additional articles abstracted in ACP Journal Club
Evid. Based Med. 2006;11:126-126.
FULL TEXT
Sophia
Emerg. Med. J. 2006;23:664-664.
FULL TEXT
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
Giugliano and Braunwald
J Am Coll Cardiol 2006;48:386-395.
FULL TEXT
|
